Summary and Conclusion
CHAPTER ELEVEN: QUALITATIVE REVIEW OF THE U.S. MARKET FOR MOLECULAR ONCOLOGY TESTS: BCR/ABL, BLADDER CANCER, AND HER2NEU
Background
BCR/ABL
Her-2/Neu
Bladder Cancer
Summary, and Conclusion
CHAPTER TWELVE: QUALITATIVE REVIEW OF THE U.S. MARKET FOR TISSUE TYPING TESTS-HLA
Background
Findings, Summary and Conclusion
CHAPTER THIRTEEN: QUALITATIVE REVIEW OF THE U.S. MARKET FOR MOLECULAR TESTS FOR INHERITED DISEASES: CYSTIC FIBROSIS (CF) AND FRAGILE X SYNDROME
Background
Cystic Fibrosis (CF)
Fragile X
Summary and Conclusion
CHAPTER FOURTEEN: QUALITATIVE REVIEW OF THE U.S. MARKET FOR MOLECULAR TESTS FOR RESPIRATORY INFECTIONS: INFLUENZA A/B, GROUP A STREP, MTB (TUBERCULOSIS), BORDETELLA PERTUSSIS, ADENOVIRUS, AND RESPIRATORY VIRUS
Background
Market Breakdown by Vendor Market Share
Summary and Conclusion
CHAPTER FIFTEEN: QUALITATIVE REVIEW OF THE U.S. MARKET FOR MOLECULAR TESTS FOR COMMUNICABLE DISEASES: CMV (CYTOMEGALOVIRUS), EBV (EPSTEIN-BARR VIRUS), GROUP B STREP, AND ENTEROVIRUS
Background
Market Breakdown by Vendor Market Share
Summary and Conclusion
APPENDIX A: TESTS MOST DESIRED BY RESPONDENTS
If current limitations or barriers did not exist, what are the three molecular tests that your lab would most like to add to its test menu in the next year?
APPENDIX B: TESTS LABS WILL ADD TO TEST MENU
Q: Is your lab seriously considering adding to its test menu in the next year or two?
APPENDIX C: TESTS REQUESTED THAT LAB CANNOT OFFER
Q: Are there any molecular tests for w
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |